Last reviewed · How we verify
NCT06671327
Preemptive Analgesia Of Dexmedetomidine Reduces Per-operation Pain
Phase 4 trial testing Preemptive Dexmedetomidine injection in Pain Management in 208 participants. Not yet recruiting.
23 June 2025
Quick facts
| Lead sponsor | China International Neuroscience Institution |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | health services research |
| Enrollment | 208 |
| Start date | 3 April 2025 |
| Primary completion | 23 June 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Preemptive Dexmedetomidine injection — full drug profile →
- Sodium Chloride 0.9% Inj — full drug profile →
Conditions studied
- Pain Management — all drugs for Pain Management →
- Noncardiac Surgery — all drugs for Noncardiac Surgery →
Sponsor
China International Neuroscience Institution — full company profile →
Who can join
Adults 18 to 85, any sex, with Pain Management or Noncardiac Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background:Preemptive analgesia is the initiation of analgesic regimen before the onset of nociceptive stimulation, preventing the amplification of pain due to peripheral and central sensitization and thereby reducing subsequent pain. Preemptive analgesia of dexmedetomidine (DEX) in the epidural and subarachnoid space can effectively prevent the central sensitization, and significantly reduce the phantom limb pain, residual pain after one year of lower limb amputation. Objective: To investigate the per-operative effects of DEX preemptive analgesia. Method:The patients scheduled noncardiac surgery undergoing general anesthesia were selected and divided into DEX group and Placebo group randmized. The DEX group was continuously pumped at 1.5 μg /(kg·h) for 15 minutes before induction, and 15min after induction. The Placebo group was infused with equal amounts of normal saline.The Coprimary efficacy outcome was a composite of analgesia effect, one is the Compliance Rate of IOC2 target in intra-operation, another is the the rate of none-to-slight post-operative pain assessed with the p-NRS≦3 at 12 hours after surgery \[Pain numeric rating scale was assessed with the (Numeric Rating Scale, p-NRS)\].
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06671327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pain Management
Currently open trials in the same condition.
- NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
- NCT07410000 — Ultrasound-Guided Quadro-Iliac Plane Block for Pain Management After Total Hip Arthroplasty · NA · recruiting
- NCT07467356 — Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip · Phase 3 · recruiting
- NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting
- NCT07442539 — The Efficacy and Safety of Liposomal Bupivacaine in Relieving Postoperative Pain After Hemorrhoid Surgery · NA · recruiting
Other China International Neuroscience Institution trials
Trials by the same sponsor.
- NCT06946277 — Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG · Phase 4 · not yet recruiting
- NCT06662656 — ED50 of Sufentanil for Intraoperative Analgesia · not yet recruiting
- NCT05500703 — Brain Regions and Functional Neuronal Network Characteristics of Dexmedetomidine Analgesia · Phase 4 · completed
- NCT04432675 — Effects of Crystal Solution and Colloid Solution on Mother and Fetus · Phase 4 · completed
- NCT04675372 — Dexmedetomidine Facilitate Analgesia · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06671327 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China International Neuroscience Institution
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06671327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing